Quick search:
Content Search
Result Content Research
Result Content Research
1 Science pioneer, pharma research chief, global health advocate and biotech entrepreneur Tadataka 'Tachi' Yamada has died
2 Moderna takes on a low-risk pact with CAR-T player Autolus for mRNA-based cancer drugs
3 UPDATED: Amgen halts a PhI for FLT3 BiTE while resuming dosing on another
4 Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial
5 Opinion: Pricing info with new drug approvals: Time for transparency
6 Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII
7 UPDATED: FDA's domestic biopharma inspections return to normal as agency faces backlog of 8000+
8 Eli Lilly teams up with KRAS drug pioneer Yi Liu targeting small molecule I/O with $70M upfront
9 Merck and Pfizer back a Michigan startup's mission to advance tumor profiling
10 EXCLUSIVE: Shape Therapeutics raises $112M in bid to make RNA editing — and a whole lot else — a reality
11 AstraZeneca and Amgen quietly admit tezepelumab setback as the Dupixent challenger heads to FDA
12 FDA chides Amgen over misleading banner ad for Neulasta
13 Denali slips as a snapshot of early data raises some troubling questions on its pioneering blood-brain barrier neuro work
14 AbbVie, riding the Aduhelm afterglow, handpicks beta amyloid drug for further R&D as it bails on tau
15 Going so soon? Scholar Rock CEO makes swift exit, leaving Nagesh Mahanthappa back at the helm
16 UPDATED: Janet Woodcock calls for independent investigation into Biogen and FDA relationships in unprecedented move
17 Ardelyx chops a third of its staff after stock-crushing failure in chronic kidney disease
18 BioNTech is spearheading an mRNA vaccine development program for malaria, with a tech transfer planned for Africa
19 After struggling with its sole drug for years, Marinus rides positive data to a commercialization deal in Europe
20 Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff — report
21 Tadataka Yamada, 1945-2021: Pioneer in drug development led global health at Gates Foundation
22 Polyphor axes staff as cash and options dwindle
23 With an assist from AstraZeneca, the salvage crew at Sierra bets another $216M they can resurrect an old Gilead JAK drug
24 UPDATED: Synbio unicorn Zymergen jettisons founding CEO, cuts guidance as customers report lead product doesn't work
25 Zymergen's sudden implosion shocked biotech. A lingering loan could make things even worse
26 IPOs continue to bustle as three more biotechs prepare to make the Nasdaq leap
27 Royalty Pharma competitor stirs the pot with plans for $750M IPO
28 How the biopharma industry is helping to pay for the bipartisan infrastructure bill
29 A stealthy startup is leveraging natural killer cells with 'memory-like' abilities to go after blood cancer and beyond
30 AstraZeneca takes a chance on the STING pathway with F-star
31 J&J, GV back a new single-cell approach for tackling inflammatory diseases and hacking the tumor microenvironment
32 Ribon Therapeutics is looking to break the mold for PARP inhibitors and has a slate of Big Pharma backers on board
33 Building off Pfizer investment, microbiome-focused Vedanta expands new fundraise to launch 2 studies
34 Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.0
35 Six more biotechs price public debuts just before the start of the weekend
36 UPDATED: Sanofi buys mRNA player Translate Bio for $3.2B. And the price fits a popular range for biotech M&A
37 Deerfield and ARCH back a new $200M SPAC run by California VC firm
38 UPDATED: Eli Lilly swoops in to buy a small protein drug developer and its glucose responsive insulin in $1B-plus deal
39 Covid-19 roundup: Early fall approval date of Pfizer-BioNTech jab still anticipated; EU buys 200M doses of Novavax vaccine
40 After a months-long halt on production, Emergent is back up and running in Baltimore
41 A Mubadala-backed biotech is using patient tumor tissue grown in a petri dish to change precision oncology
42 Candel gets busy IPO week moving with downsized raise as Rajiv Shukla's third SPAC goes public
43 PacBio engineers $800M buyout of sequencing rival Omniome as analysts fret over FTC action
44 BeyondSpring stock more than triples after lung cancer treatment meets endpoints in Phase 3 trial
45 From cellist to synthetic cell-ist: Jeffrey Kim scores $23M to reimagine blood tests, cell therapy
46 Bevacizumab-vikg meets endpoints in phase 3 wet AMD trial
47 Eli Lilly aims for dementia drug candidate's approval in 2022; wants to 'prioritize access'
48 Axel Hoos, the keeper of the oncology flame at GlaxoSmithKline, steps away for his next challenge at tiny Scorpion
49 Roche CEO Schwan puts 3-time Alzheimer's loser gantenerumab back in the spotlight as FDA's controversial Aduhelm OK inspires blockbuster forecasts
50 Resilience shells out $110M for bluebird bio site, kickstarting new collaboration
51 Tom Lynch moves to restructure Fred Hutch as academia, industry continue to push cell therapy into solid tumors
52 Samantha Du's Zai Lab inks surprising research collab with Schrödinger for DNA damage drug
53 Bayer poaches newest early R&D head from Roche; GlaxoSmithKline earns expanded nod for Shingrix
54 Five things for health marketers to know: Thursday, August 5, 2021
55 Endpoints News is now 5 years old. Here's how you can support us for the next phase of growth – Endpoints News
56 What does a clear majority of the biopharma industry think of the FDA approval of aducanumab? 'Horrifying' 'Dangerous' 'Confusing' 'Disaster'
57 UPDATED: Down but not out: FDA rejects Provention's diabetes drug as commercial product differs from trial drug
58 Recon: Bayer to buy US biotech Vividion for up to $2B; South Korea pledges $1.9B for COVID-19 vaccine production
59 Covid-19 roundup: Regeneron's mAB gets expanded EUA; mRNA drugmakers spike price of vaccines in EU supply deal
60 OneRecord Is Listed as One of the first Validated Applications in the CAQH National Directory of FHIR Endpoints
61 FDA slaps back small-cap's bid to repurpose 50-year-old chemotherapy
62 Endpoints News poll: Let's get your opinion on that controversial aducanumab approval – Endpoints News
63 Look back at pharma news in the week to July 30, 2021
64 Who are the luminaries driving the biggest advances in biopharma R&D? Endpoints News is asking for your nominations for a special report – Endpoints News
65 SoftBank claims $5B stake in Roche amid grand plans to invest in biotech — reports
66 Cemiplimab regimen extends OS in advanced NSCLC
67 Endpoints News announces its Women in Biopharma 2020 winners
68 Amgen adds new NC plant to the list as part of $1B manufacturing expansion plans stateside
69 Legacies: 60 biopharma pioneers over 60 who helped birth a tech revolution in the making
70 Endpoint Security and its Critical Need Today
71 Syxsense Releases Two New Solutions for Remediating Endpoint Security Vulnerabilities
72 DIU rethinking cyber endpoint protections through advanced deception tools
73 Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio
74 The 20(+1) under 40: Inside the next generation of biotech leaders
75 Scribe, Jennifer Doudna's newest startup, nabs a mega-round and a vocal investor
76 Gilead lands in North Carolina with a plan to hire 300 for new center
77 Endpoints News names the Endpoints 11, its list of 2020's most promising biopharmas — live event to be held today
78 Pfizer puts the pressure on Eli Lilly's JAK inhibitor Olumiant with new data in alopecia areata
79 ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'
80 IPO Tracker – Endpoints News
81 JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
82 Outbidding 14 others and then themselves: How Amgen spent $2 billion on a biotech that had been on the brink
83 Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
84 Elastic Announces the Launch and General Availability of Limitless XDR in Elastic Security, General Availability of Elastic Agent, and Centralized Management of Elastic Enterprise Search
85 Nobel laureate David Baltimore throws his weight behind I/O startup looking to craft off-the-shelf CAR therapies
86 In one of their first ever acquisitions, Relay bets $85M cash on a new AI-based screening approach
87 An EU biotech looks to rewrite the ugly history of phosphatases, and it's taking $24M in funding to get off the ground
88 CVS splashes into clinical trial services, leaning on local roots to change the game in terms of patient engagement
89 Hal Barron's chase for genetic clues leads GlaxoSmithKline back to neuro — and makes new biotech partner $700M richer overnight
90 Polyphor mulls future after PhIII cancer program crashes
91 Eli Lilly's Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, Woodcock says
92 Third time's the charm as Heron wins FDA nod for non-opioid anesthetic Zynrelef
93 Galapagos disappoints again as 2 key readouts fail to generate much enthusiasm for Gilead's fading partner
94 Tim Lu is ready to take his AI-focused biotech to the next level with first big fundraising round
95 UPDATED: Apellis bags FDA nod for Soliris challenger with a different pathway to PNH — but can it slay the giant?
96 Startup sets out to tackle the gene therapy manufacturing crisis
97 FDA grants priority review to Keytruda for stage II resected high-risk melanoma
98 Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
99 Mineralys emerges with a new take on an old idea for the treatment of hypertension and $40M to play with
100 Exclusive: Microsoft, Sam Altman back a new AI biotech upstart